Jacqueline C. Barrientos, MD, MS

Jacqueline C. Barrientos, MD, MS, discusses exciting novel combination strategies that are being presented at the 2019 ASH Annual meeting.

Jacqueline C. Barrientos, MD, MS, discusses the role of acalabrutinib, a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia, but not yet approved.